Table 1.
Clinical trials evaluating combination of epigenetic inhibitors and venetoclax.
| Epigenetic drug combination with venetoclax | Cancer typea | Phase, trial ID |
|---|---|---|
|
| ||
| DNA methyltransferase inhibitors | ||
| Azacitidine | AML | II, NCT03466294 |
| AML | II, NCT04267081 | |
| AML | II, NCT03573024 | |
| AML | III, NCT04161885 | |
| AML | III, NCT04102020 | |
| AML | III, NCT02993523 | |
| AML | II, NCT04062266 | |
| AML | II, NCT04424147 | |
| AML | II, NCT04128501 | |
| MDS/CMML | I/II, NCT04160052 | |
| MDS | III, NCT04401748 | |
| MDS | I, NCT02966782 | |
| MDS | I, NCT02942290 | |
| MDS/CML | I/II, NCT04550442 | |
| Decitabine | AML | I, NCT03844815 |
| AML | II, NCT04476199 | |
| AML/MDS | II, NCT03404193 | |
| Azacitidine or decitabine | AML | III, NCT03941964 |
| AML | I/II, NCT02203773 | |
| Azacitidine and anti-PD-1 | AML | II, NCT04284787 |
| Azacitidine, decitabine and salsalate | MDS | II, NCT04146038 |
| Azacitidine and lintuzumab-Ac225 | AML | I/II, NCT03932318 |
| Azacitidine and APR-246 | TP53-mutant myeloid malignancies | I, NCT04214860 |
| Azacitidine and pevonedistat | AML | I, NCT04172844 |
| AML | II, NCT04266795 | |
| AML | II, NCT03862157 | |
| Azacitidine and gilteritinib | AML/MDS | I/II, NCT04140487 |
| Azactidine and trametinib | AML/MDS | II, NCT04487106 |
| Azacitidine and magrolimab | AML | I/II, NCT04435691 |
| Decitabine and nivolumab | AML | I, NCT04277442 |
| Decitabine and quizartinib | AML/MDS | I/II, NCT03661307 |
| Decitabine and ponatinib | AML/CML | II, NCT04188405 |
| ASTX727 (decitabine and cedazuridine) | AML | I, NCT04657081 |
| MDS/CML | I/II, NCT04655755 | |
| Azacitidine and ivosidenib | IDH1 mutant AML/MDS | Ib/II, NCT03471260 |
| Enasidenib | IDH2 mutant AML | Ib/II, NCT04092179 |
| Histone deacetylase inhibitors | ||
| Fimepinostat and rituximab | Lymphomas | I, NCT01742988 |
| BET protein family inhibitors | ||
| ABBV-075 | AML or solid tumors | I, NCT02391480 |
a
AML, Acute myeloid leukemia; CML, chronic myelogenous leukemia; CMML, chronic myelomonocytic leukemia; MDS, Myelodysplastic syndrome.